AN ACT relating to step therapy protocols.
Summary
Amend KRS 304.17A-163 to permit insurers to require insureds to try biosimilar biological products prior to providing coverage for the equivalent branded prescription drug under certain circumstances; make findings and establish intent of Act.
Bill status
signed
all 5 stages cleared
Introduction
Jan 2024
Committee Review
Feb 2024
House Passage
Mar 2024
Senate Passage
Mar 2024
Signed into Law
Mar 2024
Introduced Jan 10, 2024
Signed Mar 14, 2024
Floor votes · House Feb 2, 2024
How they voted
This bill passed the Senate by voice vote (no roll call recorded).
Full legislative history
Actions timeline
Total actions
20
Key actions
7
Committee
6
Mar 14, 2024
Signed into law
signed by Governor (Acts Ch. 4)
lower
Mar 8, 2024
Upper · Passed
enrolled, signed by President of the Senate
upper
Mar 8, 2024
Lower · Passed
enrolled, signed by Speaker of the House
lower
Mar 7, 2024
Lower · Passed
3rd reading, passed 37-0
lower
Feb 27, 2024
Lower · Passed
reported favorably, 1st reading, to Calendar
lower
Feb 22, 2024
Committee
to Banking & Insurance (S)
upper
Feb 5, 2024
Committee
to Committee on Committees (S)
upper
Feb 2, 2024
Lower · Passed
3rd reading, passed 91-0 with Committee Substitute (1) and Committee Amendment (1-title)
lower
Jan 31, 2024
Lower · Passed
reported favorably, 1st reading, to Calendar with Committee Substitute (1) and Committee Amendment (1-title)
lower
Jan 24, 2024
Committee
to Health Services (H)
lower
Jan 10, 2024
Committee
to Committee on Committees (H)
lower
Jan 10, 2024
Introduced
introduced in House
lower
5 primary · 0 co-sponsors
Sponsors
Ask Maddy
·
AI policy assistant
Ask Maddy about HB 220
Scope: KY
Hi! I can help you understand HB 220. What would you like to know?
Try one of these
i
Maddy answers using official bill text and legislative records. Always verify before sharing.
Sources cited inline